CN1947721A - 表阿霉素缓释制剂的制备方法 - Google Patents

表阿霉素缓释制剂的制备方法 Download PDF

Info

Publication number
CN1947721A
CN1947721A CNA2006101221859A CN200610122185A CN1947721A CN 1947721 A CN1947721 A CN 1947721A CN A2006101221859 A CNA2006101221859 A CN A2006101221859A CN 200610122185 A CN200610122185 A CN 200610122185A CN 1947721 A CN1947721 A CN 1947721A
Authority
CN
China
Prior art keywords
epirubicin
solution
slow
preparation
polylactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2006101221859A
Other languages
English (en)
Other versions
CN1947721B (zh
Inventor
张其清
刘敏
翁建
叶社房
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanhui Pharmaceutical Co., Ltd.
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Priority to CN2006101221859A priority Critical patent/CN1947721B/zh
Publication of CN1947721A publication Critical patent/CN1947721A/zh
Application granted granted Critical
Publication of CN1947721B publication Critical patent/CN1947721B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicinal Preparation (AREA)
  • Biological Depolymerization Polymers (AREA)

Abstract

表阿霉素缓释制剂的制备方法,涉及一种载药高分子微球,尤其是涉及一种载表阿霉素聚乳酸缓释制剂的制备方法。提供一种避免使用表面活性剂,所得载药微球大小均一,表面圆滑,包封率和载药率较高,具有良好的缓释功效的表阿霉素缓释制剂的制备方法。其步骤为:将表阿霉素盐酸盐溶于DMF中,得溶液A,再加入三乙胺得溶液B,再加入聚乳酸得溶液C,再加入水得混浊液,将混浊液转移至透析袋中,并置于水中透析,搅拌,隔1~3h换水,透析后将得到的产物离心,超声,水洗,除去未包埋的表阿霉素,取沉淀物冷冻干燥,得表阿霉素聚乳酸缓释制剂。

Description

表阿霉素缓释制剂的制备方法
技术领域
本发明涉及一种载药高分子微球,尤其是涉及一种载表阿霉素聚乳酸缓释制剂的制备方法。
背景技术
聚乳酸(PLA)因具有良好的生物相容性及生物可降解性,被广泛应用于药物缓释,已成为生物降解医用材料中最受重视的材料之一。目前,聚乳酸载药微球的制备方法主要有相分离法、乳化溶剂挥发法、喷雾法等。其中乳化溶剂挥发法的应用最为广泛。乳化一溶剂挥发法是将聚合物溶解在有机溶剂中,然后,在搅拌下于水溶液中乳化,随着溶剂的挥发,聚合物微球慢慢形成。此类方法在乳化过程中要用到大量表面活性剂,如聚乙烯醇,而此类表面活性剂通常会粘附在微球表面,导致微球的生物降解性能,体内分布、药物释放特性及生物相容性等的改变。(参见文献:1、Lee,S.C,Oh,J.T,Jang,M.H,Chung,S.I.J.Control.Release,1999,59,123;2、Sjostrom,B,Bergenstahl,B,Kronberg,B.J.Pharm.Sci.,1993,82,584;3、Witschi,C,Doelker,E.Eur.J.Pharm.Biopharm,1997,43,215.)。
表阿霉素是抗肿瘤常用化疗药物,其主要作用是直接嵌入DNA碱基对之间,干扰转录过程,阻止mRNA的形成,从而抑制肿瘤细胞的生长,具有一定的抗肿瘤活性,但其对人体也有较强的骨髓抑止及心脏毒性,另外,表阿霉素在高温高湿度下不稳定,药物溶解后在室温下只能保存24h。
发明内容
本发明的目的旨在针对现有的制备表阿霉素缓释制剂的方法中的不足,提供一种避免使用表面活性剂,所得载药微球大小均一,表面圆滑,包封率和载药率较高,具有良好的缓释功效的表阿霉素缓释制剂的制备方法。
本发明的技术方案是采用透析法制备PLA载表阿霉素缓释微球。
本发明的具体步骤如下:
1)将表阿霉素盐酸盐溶于N-N二甲基甲酰胺(DMF)中,得表阿霉素盐酸盐溶液,记为溶液A;
2)在溶液A中加入三乙胺,得溶液B;
3)在溶液B中加入聚乳酸,得溶液C;
4)在溶液C中加入水,得混浊液;
5)将混浊液转移至透析袋中,并将透析袋置于水中透析,同时搅拌,隔1~3h换水;
6)透析4~48h后将步骤5得到的产物离心,超声,水洗,除去未包埋的表阿霉素,取沉淀物冷冻干燥,得表阿霉素聚乳酸缓释制剂。
按质量比N-N二甲基甲酰胺∶水∶表阿霉素盐酸盐∶聚乳酸∶三乙胺=3000∶(160~12000)∶(0.5~8)∶(5~80)∶(2~4)。聚乳酸的相对分子量最好为(0.5~5)万。透析袋的截留分子量(MWCO)最好为8000~14000。
本发明采用透析法成功制备了粒径分布窄,表面圆滑,表阿霉素在微球内分布均匀,包封率高,且有良好缓释功效的聚乳酸载表阿霉素微球。将表阿霉素制成微球,降低了表阿霉素的心脏毒性以及骨髓抑制等毒性,对肿瘤的治疗有重要意义。制备微球时将表阿霉素与一定量的三乙胺混合,可以显著延长表阿霉素在高湿高温条件下的稳定性,从而保证了载药聚乳酸微球缓释时药物的药效。因没有表面活性剂的参与,微球的生物降解性能,体内分布、药物释放特性及生物相容性等均可得到明显的改善。另外此法操作工艺简单、实施条件温和,易重复。通过改变透析所用溶剂、聚乳酸浓度、表阿霉素浓度和初始加入的水的体积可以调控微球粒径大小、粒径分布,包封率和载药率。
附图说明
图1为本发明实施例1所得微球的SEM图片。
图2为本发明实施例1所得微球的体外释放曲线。在图2中,横坐标为时间(d),纵坐标为累积释药量(%)。
图3为本发明实施例2所得微球的SEM图片。
图4为本发明实施例3所得微球的SEM图片。
图5为本发明实施例4所得微球的激光共聚焦显微镜断层扫描图。
图6为本发明实施例4所得微球的SEM图片。
图7为本发明实施例5所得微球的SEM图片。
具体实施方式
下面结合实施例对本发明作进一步说明。
实施例1:
(1)将5mg的表阿霉素盐酸盐溶于30ml N-N二甲基甲酰胺(DMF)得溶液A;(2)取10μl三乙胺加入溶液A中得溶液B;(3)称量50mg的聚乳酸(相对分子量为5000)加入溶液B中,得溶液C;(4)在溶液C中加入1.6ml水,得混浊液;(5)将混浊液转移至透析袋中,并将透析袋置于蒸馏水中透析,同时搅拌,隔2h换水;(6)8h后将步骤5得到的产物离心,超声,水洗3次,除去未包埋的表阿霉素,取沉淀冷冻干燥所得样品。所得样品测得包封率为59.6%,载药率为6.8%,通过扫描电镜观察到微球表面圆滑,粒径分布在400nm~700nm,见图1。通过粒度分析测得微球粒径平均大小为589.5nm,多分散度(polydispersity)为0.095。体外释放实验得出这种微球有缓慢释放表阿霉素得功效,药物最终释放可达70%,见图2。
实施例2:
(1)将12mg的表阿霉素盐酸盐溶于18ml N-N二甲基甲酰胺(DMF)得溶液A;(2)取12μl三乙胺加入溶液A中得溶液B;(3)称量60mg的聚乳酸(相对分子量为5000)加入溶液B中,得溶液C;(4)在溶液C中加入2ml纯净水,得混浊液;(5)将混浊液转移至透析袋中(8000~14000),并将透析袋置于蒸馏水中透析,同时搅拌,隔2h换水;(6)24h后将步骤5得到的产物离心,超声,水洗3次,除去未包埋的表阿霉素,取沉淀冷冻干燥所得样品。所得样品测得包封率为53.6%,载药率为7.4%,扫描电镜观察到微球表面圆滑,粒径分布在200nm~600nm,见图3。通过粒度分析测得微球平均粒径大小为389.7nm,多分散度(polydispersity)为0.086。
实施例3:
(1)将4mg的表阿霉素盐酸盐溶于3ml N-N二甲基甲酰胺(DMF)得溶液A;(2)取2μl三乙胺加入溶液A中得溶液B;(3)称量40mg的聚乳酸(相对分子量为1万)加入溶液B中,得溶液C;(4)在溶液C中加入0.75ml纯净水,得混浊液;(5)将混浊液转移至透析袋中(8000~14000),并将透析袋置于蒸馏水中透析,同时搅拌,隔2h换水;(5)4h后将步骤5得到的产物离心,超声,水洗3次,除去未包埋的表阿霉素,取沉淀冷冻干燥所得样品。所得样品测得包封率为30.9%,载药率为4.9%,扫描电镜观察到微球表面圆滑,粒径分布在500nm~1200nm,见图4;通过粒度分析测得微球粒径平均大小为863.5nm,多分散度(polydispersity)为0.067。
实施例4:
(1)将8mg的表阿霉素盐酸盐溶于3ml N-N二甲基甲酰胺(DMF)得溶液A;(2)取2μl三乙胺加入溶液A中得溶液B;(3)称量80mg的聚乳酸(相对分子量为1万)加入溶液B中,得溶液C;(4)在溶液C中加入12ml纯净水,得混浊液;(5)将混浊液转移至透析袋中(8000~14000),并将透析袋置于蒸馏水中透析,同时搅拌,隔2h换水;(5)4h后将步骤5得到的产物离心,超声,水洗3次,除去未包埋的表阿霉素,取沉淀冷冻干燥所得样品。所得样品测得包封率为24.6%,载药率为2.6%,通过激光共聚焦显微镜观察得出表阿霉素在微球内均匀分布,见图5;通过扫描电镜观察到微球大小均一,粒径分布在600nm~900nm,微球表面圆滑,见图6:通过粒度分析测得微球粒径平均大小为768.4nm,多分散度(polydispersity)为0.068。
实施例5:
(1)将12mg的表阿霉素盐酸盐溶于9ml N-N二甲基甲酰胺(DMF)得溶液A;(2)取12μl三乙胺加入溶液A中得溶液B;(3)称量60mg的聚乳酸(相对分子量为5000)加入溶液B中,得溶液C;(4)在溶液C中加入12ml纯净水,得混浊液;(5)将混浊液转移至透析袋中(8000~14000),并将透析袋置于蒸馏水中透析,同时搅拌,隔2h换水;(5)48h后将步骤5得到的产物离心,超声,水洗3次,除去未包埋的表阿霉素,取沉淀冷冻干燥所得样品。所得样品测得包封率为24.6%,载药率为9.1%,通过扫描电镜观察到微球大小均一,表面圆滑,粒径分布在250nm~470nm,见图7;通过粒度分析测得微球粒径平均大小为313.6nm,多分散度(polydispersity)为0.059。

Claims (4)

1.表阿霉素缓释制剂的制备方法,其特征在于其步骤为:
1)将表阿霉素盐酸盐溶于N-N二甲基甲酰胺中,得表阿霉素盐酸盐溶液,记为溶液A;
2)在溶液A中加入三乙胺,得溶液B;
3)在溶液B中加入聚乳酸,得溶液C;
4)在溶液C中加入水,得混浊液;
5)将混浊液转移至透析袋中,并将透析袋置于水中透析,搅拌,隔1~3h换水;
6)透析4~48h后将步骤5得到的产物离心,超声,水洗,除去未包埋的表阿霉素,取沉淀物冷冻干燥,得表阿霉素聚乳酸缓释制剂。
2.如权利要求1所述的表阿霉素缓释制剂的制备方法,其特征在于按质量比N-N二甲基甲酰胺∶水∶表阿霉素盐酸盐∶聚乳酸∶三乙胺=3000∶160~12000∶0.5~8∶5~80∶2~4。
3.如权利要求1或2所述的表阿霉素缓释制剂的制备方法,其特征在于聚乳酸的相对分子量为0.5万~5万。
4.如权利要求1所述的表阿霉素缓释制剂的制备方法,其特征在于透析袋的截留分子量为8000~14000。
CN2006101221859A 2006-09-18 2006-09-18 表阿霉素缓释制剂的制备方法 Active CN1947721B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2006101221859A CN1947721B (zh) 2006-09-18 2006-09-18 表阿霉素缓释制剂的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2006101221859A CN1947721B (zh) 2006-09-18 2006-09-18 表阿霉素缓释制剂的制备方法

Publications (2)

Publication Number Publication Date
CN1947721A true CN1947721A (zh) 2007-04-18
CN1947721B CN1947721B (zh) 2011-01-26

Family

ID=38017409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006101221859A Active CN1947721B (zh) 2006-09-18 2006-09-18 表阿霉素缓释制剂的制备方法

Country Status (1)

Country Link
CN (1) CN1947721B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102209531B (zh) * 2008-11-14 2014-08-27 梨花女子大学校产学协力团 高分子微球的制造方法和通过该方法制造的高分子微球
CN108434124A (zh) * 2018-06-15 2018-08-24 厦门大学 一种表阿霉素ves复合物和制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277465A1 (en) * 2000-04-24 2003-01-22 Tanabe Seiyaku Co., Ltd. Process for producing microsphere
CN1582934A (zh) * 2004-06-14 2005-02-23 王安训 喜树碱衍生物的纳米微粒、制备方法及其药物用途
CN100400032C (zh) * 2004-09-16 2008-07-09 同济大学 一种油溶性药物缓释微球的制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102209531B (zh) * 2008-11-14 2014-08-27 梨花女子大学校产学协力团 高分子微球的制造方法和通过该方法制造的高分子微球
CN108434124A (zh) * 2018-06-15 2018-08-24 厦门大学 一种表阿霉素ves复合物和制备方法及其应用

Also Published As

Publication number Publication date
CN1947721B (zh) 2011-01-26

Similar Documents

Publication Publication Date Title
Zupančič Core-shell nanofibers as drug-delivery systems
Abdul Hameed et al. Electrospun nanofibers for drug delivery applications: Methods and mechanism
US7883723B2 (en) Water soluble chitosan nanoparticle for delivering an anticancer agent and preparing method thereof
Vijayan et al. Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: In vitro and in vivo studies
KR101862416B1 (ko) 마이크로입자를 제조하기 위한 에멀전-기반 방법 및 이 방법과 함께 사용하기 위한 워크헤드 조립체
EP2644191B1 (en) Nonwoven membrane as a drug delivery system
US20100003300A1 (en) Injectable delivery of microparticles and compositions therefore
CN104136012B (zh) 制备装载有活性物质的纳米颗粒的方法
Shah et al. Chitosan and carboxymethyl cellulose-based 3D multifunctional bioactive hydrogels loaded with nano-curcumin for synergistic diabetic wound repair
Dhanka et al. Injectable methotrexate loaded polycaprolactone microspheres: physicochemical characterization, biocompatibility, and hemocompatibility evaluation
Meng et al. Tenofovir containing thiolated chitosan core/shell nanofibers: in vitro and in vivo evaluations
JP2007070332A (ja) 多糖類で機能化された水和ゲル膜を有するナノ粒子とこれを含む徐放型薬物伝達システム及びその製造方法
Norouzi et al. Emulsion electrospinning of sodium alginate/poly (ε-caprolactone) core/shell nanofibers for biomedical applications
Stevanović et al. ROS-inducing potential, influence of different porogens and in vitro degradation of poly (D, L-lactide-co-glycolide)-based material
Priya Dasan et al. Polymer blend microspheres for controlled drug release: the techniques for preparation and characterization: a review article
Liu et al. Biodegradable and dissolvable resveratrol nanocrystals non-silicon microneedles for transdermal drug delivery
CN1947721B (zh) 表阿霉素缓释制剂的制备方法
Ebhodaghe A scoping review on the biomedical applications of polymeric particles
Joung et al. PLGA microparticle-embedded thermosensitive hydrogels for sustained release of hydrophobic drugs
Zhao et al. Development and optimization of insulin-chitosan nanoparticles
Lee et al. Thiolate poly (lactic-co-glycolic acid) nanofibers loaded with dexamethasone and ropivacaine show enhanced sustained release in the treatment of neuropathic pain through a local therapy technique
CN115920126A (zh) 负载植物外泌体的聚羟基脂肪酸酯微球及其制备方法
CN114748637B (zh) 苯硼酸修饰型纳晶药物稳定系统及其制备方法和应用
Ahmady et al. Alginate carrier as a controlled thymol delivery system: Effect of particle size
EP2552412A2 (en) Emulsions for microencapsulation comprising biodegradable surface-active block copolymers as stabilizers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: HISUN HUIRUI PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: XIAMEN UNIVERSITY

Effective date: 20140917

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 361005 XIAMEN, FUJIAN PROVINCE TO: 200032 XUHUI, SHANGHAI

TR01 Transfer of patent right

Effective date of registration: 20140917

Address after: 200032, room 10, building 596, block A, No. 1003 middle Longhua Road, Shanghai, Xuhui District

Patentee after: HAIZHENGHUI PHARMACEUTICAL CO., LTD.

Address before: Xiamen City, Fujian Province, 361005 South Siming Road No. 422

Patentee before: Xiamen University

DD01 Delivery of document by public notice
DD01 Delivery of document by public notice

Addressee: HAIZHENGHUI PHARMACEUTICAL CO., LTD.

Document name: Notification of Passing Examination on Formalities

CP03 Change of name, title or address

Address after: 311404 2 Hai Zheng Road, Xu Kou Town, Fuyang District, Hangzhou, Zhejiang

Patentee after: Hanhui Pharmaceutical Co., Ltd.

Address before: Room 1003, 10th floor, Block A, 596 Longhuazhong Road, Xuhui District, Shanghai

Patentee before: HAIZHENGHUI PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address